Table 1.
CDP870-00425 Phase 2 trial: Active RA patients (n = 203) | |||||
SC CZP or placebo every 4 weeks for 12 weeks. | |||||
Endpoints (week 12) | Placebo | CZP 50 mg | CZP 100 mg | CZP 200 mg | CZP 400 mg |
ACR20 | 15% | 21% | 20% | 34% | 60% |
ACR50 | 0% | 8% | 5% | 17% | 40% |
ACR70 | 0% | 5% | 3% | 7% | 29% |
RA, rheumatoid arthritis; SC, subcutaneous; CZP, certolizumab pegol; ACR, American College of Rheumatology.